NOVACYT SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC

Further validation of Novacyt’s expertise in developing assays for clinical applications Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into

Visit Page

FOR THE THIRD YEAR RUNNING NOVACYT IS PLACED IN THE TECHNOLOGY FAST 500 EMEA AWARDS

Novacyt Fast 500 PR Paris, France and Cambridge, UK – 2 January 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte’s Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth in

Visit Page